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Patient and public involvement in Health Technology Assessment (HTA) is gaining 
increased interest among research and policy communities. Patients’ organizations 
represent an important link between individual patients and the health system. Social 
theories are increasingly being used to explain doctor-patient-system interactions, 
expanding understanding beyond the mere clinical perspective. In this sense, patient 
involvement in HTA can also be considered through the Habermas’ theory of communicative 
action. From a Habermasian perspective, HTA as part of the instrumental rationality 
contributes to increased efficiency of resource use within the system; however, such 
rationalization threatens to colonize the lifeworld by making it ‘increasingly state 
administered with attenuated possibilities for communicative action as a result of the 
commercialization and rationalization in terms of immediate returns’. Using Habermasian 
system/lifeworld framework, this paper explores opportunities and obstacles to patient 
involvement in HTA, whereby trying to understand current and possible roles of patients’ 
organizations as a mediating force between HTA as a function of the system and the 
lifeworld, represented by patients. 
 
Keywords 
Technology Assessment, biomedical; patient participation; communication; policy; health 
resources; social theory 
 
Acknowledgements 
The authors would like to thank Dr. Katy Cooper, University of Sheffield, School of Health 
and Related Research for her inputs and support in the work preceding the development of 
this manuscript. 
Funding statement 






Patient and public involvement in Health Technology Assessment (HTA) is gaining 
increasing interest among research and policy communities (1), and in the same way, as 
HTA is used to inform health coverage decisions, public and patient interest in HTA has 
increased (2). However, over the years, to inform the efficient resource use for a growing 
healthcare demand, a more rapid and less-resource intensive production of HTAs has been 
imposed (3), resulting in shorter HTA reports (4), limiting patients’ and public participation 
and hampering assessment of the wider implications of using a health technology (5). 
Countering this, the patient organizations become an important link between individual 
patients and the health system (6), advocating that patients’ perspectives should be fully 
understood in the deliberative HTA process (2). While patient and public involvement in HTA 
is usually analyzed under a common framework (7), our analysis is concerned with patient 
involvement, whereby particular focus is put on the role of their organized form of voicing 
needs and interests – patients’ organizations. 
Social theories are increasingly being used to explain doctor-patient-system interactions, 
expanding understanding beyond the mere clinical perspective (8). Patient involvement in 
HTA can also be considered through Habermas’ theory of communicative action that 
describes social life through two distinct spheres: the system and the lifeworld, each 
governed by different rationality; the system being largely a subject of instrumental rationality 
– orientated towards structure, systematization and successful outputs; whilst the lifeworld is 
the depiction of the communicative rationality – oriented towards reasoning, interpretation, 
exchange and achieving mutual understanding (9). Habermas’ influential work has been 
used to contextualize and understand different aspects of health and healthcare, including 
patient-provider interactions, the role of medicines in society, and patient involvement in 
research, design and delivery of health services (10-13). Using a Habermasian 
system/lifeworld framework which helps bridge micro- and macro-social perspectives, this 
paper explores the opportunities and challenges to patient involvement in HTA, whereby 
trying to understand the current and possible role of patients’ organizations as a mediating 
agent between the HTA as a function of the system and the lifeworld, represented by 
patients. 
The system: HTA as a social construct 
HTA is a process of critical and systematic assessment that seeks to inform decision-makers 
about the most efficient use of health technologies, while taking into consideration context-
specific social, economic and ethical implications of its use (3). Habermas’ system/lifeworld, 
stemming originally from Marx’s interpretations of society and the Parsonian conception of 
the social system (14), is concerned predominantly with the material exchanges of the 
society and structuralism, whereby all means, including human beings are utilized for the 
successful production of actions and outputs (15); and in the context of healthcare - for 
delivery of health services and production of health gains. Thus, from a Habermasian 
perspective, HTA as part of the instrumental rationality contributes to increased 
effectiveness and efficiency of resource use within the system. HTA as a function of health 
economics attempts to give answers to how scarce health resources can be used to meet 
patients’ needs, while, as argued by Small et al (16), considering that the “predominant 
production function for health is health care”. But, the relevant social consideration of the 
lifeworld is health, not health care. To the lifeworld, health is not just the product of health 
care, but of an array of social determinants, and at the same time, access to healthcare is 
not merely an end-product, but rather a prerequisite for ensuring quality of life and wellbeing 
(16). Britten (13) categorizes it as a divergence whereby “the lifeworld/system distinction 
points out the tension between the experiences, needs and concerns of lay people, patients 
and carers on one hand and, on the other, the need to make profit in a capitalist society 
(healthcare industry) and the role in enacting government policies […] Individuals who 
become ill not only find themselves as members of the familiar lifeworld, but also members 
of an unfamiliar healthcare system with different rules and modes of behavior” (13) (p.19). In 
other words, the rationalization of healthcare through HTA threatens to colonize the lifeworld 
by making it “increasingly state administered (‘juridified’) with attenuated possibilities for 
communicative action as a result of the commercialization and rationalization in terms of 
immediate returns” (12) (p.13). Patient involvement in HTA is one of the possible solutions, 
that despite bringing benefit, also poses challenges, including those of ensuring 
representativeness and reducing the patient bias that can either stem from their experience 
with the disease (disease-specific) or be imposed by the industry and technology developers 
(industry-induced).  
The Lifeworld: Patients and HTA 
In Habermas’ system/lifeworld dyad, patients and the public represent the lifeworld, where 
‘communicative action’ plays an essential role that is central to human relationships (14), 
through which all cultural, experiential and knowledge exchanges occur (9, 13). Within the 
lifeworld, communication and exchanges have intrinsic value and aim to achieve common 
understanding without any dominance or power imbalance between individuals (11). In other 
words, patients’ voice in HTA, brings the lifeworld component of direct participation and 
experience of those affected by the illness or condition (17).  Stewart et al (18) consider that 
the patient’s contribution to the healing process includes “the patient’s personal and 
subjective experience of sickness; the feelings, thoughts and altered behavior of someone 
who feels sick” (p.35). Therefore, behavior and thus the influence of patients and their 
relationship with providers is inevitably bound to the “complex whole which includes 
knowledge, belief, art, morals, law, custom and any other capabilities and habits acquired by 
man as a member of society” (19). Yet, patients’ behavior and personal characteristics such 
as gender, ethnicity and social class represent the totality of a person's learned, 
accumulated experience, which is socially transmitted through communication, and 
inevitably influence the balance of power in achieving the common understanding. 
Patients’ influence on decision-making was explained by Mishler (10) through provider-
patient encounters, whereby “the voice of the lifeworld refers to the patient’s contextually-
grounded experiences of events and problems in her life” (p.104). In this sense, the personal 
identity as conceived by Mead (20) and Durkheim (21) arises as a structure that results from 
taking over socially generalized expectations, and “an organized set of attitudes that one 
takes over from one’s reference persons” (22) (p.58). Habermas refers to culture, society 
and personality as structural components of the lifeworld, where individuality is expressed 
through the heightened claims to autonomy and self-realization. Thus, beyond the 
specialized knowledge and system realities, individuality plays a significant role in shaping 
the communicative action and health outcomes (13), including preferences for decisions 
made through the HTA process. 
Thus, the role of patients in medical decision-making needs to be viewed through its 
perspective of complex, contextualized and meaningful interaction with the health system, 
including participation in the HTA process. Increasing access to information, reducing the 
knowledge gap between providers and patients and deprofessionalization of medicine (12) 
become enablers for the empowered patient’s negotiation and influence on decision-making, 
as part of the resistance to the colonization of the lifeworld by either the state or market 
forces (23).  
System-Lifeworld interaction: patient organizations’ role in HTA 
A further important aspect of Habermas’ theory is what he termed the colonization of the 
lifeworld by the system. This is argued to arise in modern societies and it involves increasing 
systematization of particular areas of the lifeworld, leading to deviation from or stagnation of 
the original purpose of the lifeworld and its communicative action (11). In terms of patient 
involvement in HTA, exemplifying the system/lifeworld interaction, such systematization and 
superimposition could be illustrated through, for example, pressure of the system on the 
decision-makers to make resource-efficient decisions, shortening the comprehensive HTA 
analysis and process, manifest as increasingly limited consideration of the wider implications 
of the use of a health technology. Participants in the HTA process in general are expected to 
provide deliberation and guidance for decisions that would ensure efficacy and at the same 
time fairness in resource allocation. Yet, alongside the intention for ensuring distributive 
justice, there arises a tension from the systems’ rationality to maximize output at an optimal 
cost, as a prerequisite for them being part of the system and its presupposed efficiency (14). 
In turn, this leads to limited space for communicative rationality, producing patient 
dissatisfaction and unmet expectations that represents a failure to reach common 
understanding (13). 
However, patient involvement in HTA, as mentioned earlier, brings challenges and ethical 
dilemmas into answering the question on how to develop a representative and robust 
patient-based evidence with minimized disease-specific or industry-influenced patient bias 
(24). To this end, a strengthened role of patient organizations, emphasizing their mediating 
power between the bias of the individual experiences and the technocracy of the HTA 
process, alongside their referential knowledge and expertise gathered from their expert-
patient community can respond to some of the challenges and ethical dilemmas, adding 
quality and objectivity to the patient involvement in HTA process. In a way, patient 
organizations’ mediating power comes from the duality of their role; on one side, aligning 
with the system’s rules of efficiency and effectiveness for the purpose of having to sustain 
their operations and existence, and at the same time being themselves part of the lifeworld, 
through their constituency – the patients. Thus, it is arguable that their position can be 
considered more informed than that of the system, in regards to patients’ needs and 
preferences. Patient organizations are accountable before patients as their constituency and 
raison d'être, and are thus expected to be inclined to represent their voice in the HTA 
process. Yet, often financial support for their work comes from commercial sources with 
vested interests – namely, the pharmaceutical and technology development industry. As 
formally registered law-governed entities they are obligated to transparency regarding any 
contributions that might influence their impartiality in providing inputs in the HTA process 
(such as in Canada or UK) (25). However, such impartiality has been questioned (26), and 
widely debated (27, 28), suggesting that further insights and research is needed on the issue 
(29). In addition, it is recognized that there is a potential danger in over-representing certain 
groups, perhaps due to their size, power, influence or even sympathy and that this may not 
ensure distributive justice is optimized even if they are patient-centered groups and reside 
more within the lifeworld. However, such concerns are in fact central to Habermas' theories 
and in particular to the concept of discourse ethics. This involves individuals and groups 
engaging in communicative acts - what he terms ideal speech situations - to ensure that 
what is considered appropriate and right is mutually agreed in intersubjective terms. The 
overt influence of certain patient groups in the HTA process is not necessarily a problem if 
appropriate means of discourse ethics are put in place; this would require all parties in the 
process to consider both the individual (patient) perspective but also consider rational 
appeals to universality (in a Kantian sense) and the final decision would be one that 
recognized and accommodated both these positions for all parties.  
Finally, their investment in building independent capacity for patient advocacy and expertise 
becomes an important currency in maintaining reputation and enjoying recognition by the 
system as a formal partner in healthcare design and delivery – one that is expected to yield 
in better quality (and less biased) input to any HTA or policy-making process in a given 
context (25), and one they are likely motivated to protect at any cost.  
Conclusion 
However different the system and lifeworld rationalities are, they remain interdependent and 
in continuous interaction (14, 30). The actual type of interaction between the two spheres – 
in this case the patient and the HTA process – is what determines the product and the 
outcome of such interaction. Through the duality of their role, patient organizations can act 
as mediating agents between the instrumental rationality of the HTA process and the 
communicative rationality of the lifeworld represented through patients in achieving mutual 
understanding within the deliberative HTA process. However, there is a fine line between 
substantial representation of patients’ needs and tokenistic approach to their involvement, as 
noted by Gibson et al (31), who point out the danger of pathologies that arise with 
colonization, by lack of attention to service users' own perspectives and treating patients 
solely as a source of information which “can be fed into a bureaucratic planning process and 
a tendency to treat healthcare decision making as a purely technical process, thus 
privileging the knowledge and expertise of technocrats over that of lay people”. To this end, 
it can also be argued that some patient organisations act as instruments to further the 
colonization of the lifeworld by the system. Thus, enabling articulation of patient voice 
through strengthened patient organizations participation supports the premise that 
prioritizing the lifeworld would contribute to better outcomes and more humane treatment of 
patients as unique human beings, but would also contribute to higher compliance with the 
recommendations and medical advice provided to them (11).  
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